Can a new drug combo outperform standard care for a common type of heart failure?
NCT ID NCT05508035
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial is testing whether sacubitril/valsartan, a newer heart failure medication, can improve heart function and reduce harmful heart remodeling better than the older drug ramipril. The study enrolls adults with ischemic heart failure (caused by reduced blood flow to the heart) who have a moderately reduced ejection fraction (40-49%). Participants are randomly assigned to receive either sacubitril/valsartan or ramipril, and the main goal is to see if the newer drug leads to greater improvements in heart size and pumping ability over 12 months, as measured by MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacubitril/valsartan (a combination drug) compared against ramipril (an ACE inhibitor)
- What this could lead to
- If successful, this could establish sacubitril/valsartan as a better option than ramipril for improving heart function and preventing further damage in patients with ischemic heart failure with mid-range ejection fraction.
- What could go wrong
- This is a phase 3 trial, but results may not show a clear benefit over ramipril, and the drug may have side effects like low blood pressure or kidney issues. The outcome depends on long-term follow-up.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH MODERATELY REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
RECRUITINGKrakow, Lesser Poland Voivodeship, 31-202, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.